

Date 06 May, 2025

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Stock Code: BSE – 530549 / NSE – SHILPAMED

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

.....

**Approval by European Medicines Agency, for Shilpa Medicare Ltd.
Unit VI, Bengaluru.**

This is to inform you that Shilpa Medicare Limited, Unit VI, Dabaspeth, Bengaluru, Karnataka, India has received GMP approval from EMA (European Medicines Agency).

The inspection was conducted by Finnish Medicine Agency on behalf of EMA, from March 10 – 14, 2025 and concluded with few minor observations. This GMP approval is for manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms being produced from this facility - Oral Mouth Dissolving Films and Transdermal Systems. The Unit is already approved by MHRA, UK and TGA, Australia.

Oral Mouth Dissolving Films and Transdermal Systems are both, technology intensive, niche and complex dosage forms which offer significant advantages over conventional oral dosage forms in terms of patient convenience, dosing compliance and quick or sustained drug delivery for local and systemic therapy.

This Unit is currently supplying Oral Film products to US and other markets. This approval will enable the company to secure approval and market its range of Oral Film products and Transdermal Patches in the entire European Union. The Company has a pipeline of products under the Oral Film and Transdermal Patch dosage forms which are approved, under approval and in advanced stages of development.

For **SHILPA MEDICARE LIMITED**

Ritu Tiwary
Company Secretary & Compliance Officer